T-X-P Therapeutics

TXP Therapeutics is a Swiss biotechnology company specializing in the development of highly potent and selective melanocortin receptor agonists. The company's primary focus is on preventing and treating organ failure and inflammation-related conditions, particularly in the context of major surgery and critical care. Their lead programs utilize synthetic peptide analogs designed to activate the body's natural anti-inflammatory and cytoprotective pathways. TXP's technology platform aims to address significant unmet needs in ischemia-reperfusion injury and systemic inflammatory response syndrome (SIRS). The company was acquired by Quest Pharmatech to integrate its peptide assets into a broader portfolio of therapeutic solutions.